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Abstract: Manganese-based contrast agents (MnCAs) have
emerged as suitable alternatives to gadolinium-based contrast
agents (GdCAs). However, due to their kinetic lability and
laborious synthetic procedures, only a few MnCAs have found
clinical MRI application. In this work, we have employed
a highly innovative single-pot template synthetic strategy to
develop a MnCA, MnLMe, and studied the most important
physicochemical properties in vitro. MnLMe displays optimized
r1 relaxivities at both medium (20 and 64 MHz) and high
magnetic fields (300 and 400 MHz) and an enhanced r1
b =
21.1 mM1 s1 (20 MHz, 298 K, pH 7.4) upon binding to
BSA (Ka = 4.2  10
3 M1). In vivo studies show that MnLMe is
cleared intact into the bladder through renal excretion and has
a prolonged blood half-life compared to the commercial
GdCA Magnevist. MnLMe shows great promise as a novel MRI
contrast agent.
Introduction
Magnetic resonance imaging (MRI) is a powerful non-
invasive medical imaging technique that produces high-
resolution 3D images of anatomy and the physiological
function.[1] MRI monitors the difference between longitudinal
(T1) and transverse (T2) relaxation times of water protons in
the body. Different tissues in the body present different T1
and T2 values due to the differential water content and
chemical surroundings of the water protons, which allows in
some cases to differentiate healthy from diseased tissues.
However, the inherent contrast offered by the water relax-
ation times (T1 and T2) of normal and abnormal tissues is
often subtle, which limits the accuracy of detection.[1a] The
contrast of specific organs, tissues, and disease progression, is
enhanced when contrast agents (CAs) are applied to shorten
the relaxation rate (R1,2 = 1/T1/2) of water protons within these
tissues.
Gadolinium-based MRI contrast agents (GdCAs) have
been applied since 1988 and used in clinics due to their kinetic
inertness, fast clearance, and favorable hepatic/renal/hepato-
biliary elimination.[2] Nevertheless, free Gd3+ ions are toxic in
biological systems due to the similarity in ionic radius
(0.94 ) with that of the Ca2+ ion (0.99 ).[3] Recently, due
to the weaker kinetic stability of acyclic GdCAs particularly
when applied in vivo, a red flag has been raised for most of the
clinical GdCAs due to aggravated nephrogenic systemic
fibrosis (NSF)[4, 5] and the detection of Gd3+ deposition in the
brain upon recurrent injection of GdCAs.[6] Due to these
concerns, the European Medicines Agency (EMA) has
suspended the marketing authorizations of the four acyclic
GdCAs.[7, 8] The US—Food and Drug Administration (FDA)
also advised against the use of linear acyclic GdCAs in
patients with compromised renal function.[7, 9] To overcome
these hurdles, it is essential to develop and implement Gd3+-
free MR contrast agents to clinical routine. Manganese-based
contrast agents (MnCAs) have been introduced as safer
alternatives[10] to GdCAs. Mn2+ has five unpaired d electrons,
long electronic relaxation time, and rapid water exchange.
These properties are ideal for CAs capable of enhancing T1
contrast.[11] Manganese is a biogenic and vital metal found in
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most tissues (mean serum concentration of 0.5–1.2 mgL1). It
is required for bone development, neuronal health and, other
physiological and cellular (mitochondrial) functions.[12] It
plays an essential role in amino acid, lipid, protein, and
carbohydrate metabolism.[12a] It is also involved in glycogen
storage in the liver, protein digestion, and the synthesis of
cholesterol and fatty acids.[13] Despite the increased interest in
MnCAs development, no MnCAs are clinically available.[14]
Therefore, there is significant interest in the development of
next-generation MnCAs, with 1) high thermodynamic stabil-
ity, 2) kinetic inertness under physiological conditions, and 3)
fast in vivo clearance. A major challenge in developing
MnCAs is that Mn2+ shows a limited crystal field stabilization-
lower thermodynamic stability-by most ligands compared to
the other transition metals from the Irving-Williams ser-
ies.[15, 16] It is thus of critical importance to design MnCAs with
superior kinetic inertness. As demonstrated for lanthanide-
based complexes, kinetic inertness is crucial when applying
safe CAs in vivo.[17]
The MRI contrast efficiency of CAs, the relaxivity (r1), is
proportional to the number of water molecules present in its
first coordination sphere.[18–22] Despite the advantageous
capabilities of producing brighter MR contrast, only a few
bishydrated MnCAs have been reported so far, and none
showed favorable kinetic inertness for in vivo applica-
tions.[16, 23] In particular, pyridyl-based pentadentate ligands
with N5 or N3O2 donors have seen interest due to the
formation of a stable pentacoordinate planar coordination
structure with Mn2+.[24] This structure provides an additional
feature for coordinating two additional axial water molecules
or counter anions.[25] Another critical parameter for the
efficiency of contrast agents is a slow rate of molecular
reorientation defined as the rotational correlation times (tR).
This can be achieved by developing macromolecular contrast
agents (i.e., proteins, functionalized gold nanoparticles,
quantum dots, dendrimers, nanotubes, liposomes)[26, 27] by
conjugating the paramagnetic metal complex into a slowly
tumbling macromolecule,[28] or incorporating functional
groups that are capable of interacting non-covalently with
macromolecules such as blood plasma proteins.[29] The latter
received great attention as they render opportunities to
design and synthesize contrast agents with specific groups that
target macromolecules to prolong their lifetime in the blood-
stream.[30, 31] Thus there is need to develop new MnCAs
bearing hydrophobic groups, to facilitate the binding to
human serum albumin (HSA) and improve the relaxometric
properties and pharmacokinetics, which result in optimal
blood pool agents.
Herein, we report a new, economic, and straightforward
one-pot synthesis of a Schiff-base type diacetylpyridyl carbo-
hydrazide-based Mn2+ complex (MnLMe) as a T1 contrast
agent. MnLMe showed kinetic inertness to zinc-transmetalla-
tion and displayed enhanced T1 relaxivity upon non-covalent
binding with serum albumin. The kinetic inertness of the
acyclic Mn2+ complex (MnLMe) has been examined concern-
ing time course relaxivity, zinc-transmetallation, spectral
absorption titration, in vivo excretion stability and NMRD
experiments. In vivo, MRI was also conducted in healthy mice
to assess T1 enhancement in tissues, biodistribution, and
elimination pathways of MnLMe.
Results and Discussion
Design, Syntheses, and Structural Analyses
We have synthesised a Schiff-base type (2,6-diacetylpyr-
idine bisacetylhydrazone) manganese complex in a facile
single-pot template method. The mononuclear Mn2+ complex
MnLMe was synthesised by refluxing 1:2:1 molar mixture of
2,6-diacetylpyridine, acetyl hydrazine and MnCl2 in methanol
(Scheme 1). The isolated yield of the MnLMe was found to be
91%, which is higher than the yields of other derived
heptacoordinated Mn2+ complexes.[25b, 32, 33] To explore the
structure of the ligand LMe by NMR, we synthesised the
diamagnetic Zn2+ analogue ZnLMe along with MnLMe ; both
complexes were fully characterized by elemental analyses,
conventional spectroscopy, and X-ray crystallographic tech-
niques. The 1H-NMR of ZnLMe in D2O (Figure S1) shows
a single set of aromatic signals (d = 8.2 to 8.0 ppm), and two
resonances at d = 2.23 to 2.44 ppm corresponding to the
aliphatic methyl protons. The 13C-NMR spectrum of ZnLMe
(Figure S2) is consistent with the proposed structure. It
displays seven expected resonances, 12.6 ppm, and 19.7 ppm
for the CH3 nuclei, a peak at 124.5 ppm for the azomethines
(C=N), three aromatic signals between 143 ppm and 148 ppm
and a single resonance at 173 ppm corresponds to the
carbonyl groups.
The complexes (MnLMe and ZnLMe) are highly soluble
( 96 and 84 mgmL1, respectively) in 50 mM HEPES buffer
(pH 7.3). They display two intense absorption bands at 213
and 275 nm, attributed to the intra-ligand p-p* and n-p*
transitions within the coordinated pyridyl ring and electron
localized carbohydrazones (Figure S3). The MS (ESI+) anal-
ysis of MnLMe and ZnLMe in methanol (Figures S4, S5)
confirms 1:1 stoichiometry between chelate and M2+ ion
(M = Mn and Zn), where the spectral profiles exhibit peaks at
m/z of 365.045 & 329.068 and 374.18 & 339.14 corresponding
to the expected ([M(LMe)(Cl)]+) and ([M(LMeH+)]+) spe-
cies, respectively. Overall, the spectroscopic and analytical
data are consistent with the proposed structural formula of
the complexes.
Crystal Structures of MnLMe and ZnLMe
The Mn2+ complex MnLMe crystallizes in monoclinic space
group P21/c with a single molecule in the asymmetric unit
Scheme 1. Synthesis of complexes MnLMe and ZnLMe.
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(Z = 4). The ORTEP diagram for MnLMe is presented in
Figure 1. The Mn2+ ion is formally 7-coordinate in a pentag-
onal bipyramidal geometry. The equatorial plane is composed
of the N3O2 coordination environment of the PyCOHz ligand;
the Mn-N distances lie in the range 2.2872(18) to 2.979(10) 
and the Mn-O1 and Mn-O2 distances are 2.2446(16) and
2.2418(16) , respectively. The axial ligands, chloride (Mn-
Cl1 = 2.499(8) ), and water (Mn-O3 = 2.173(2) ) show
little deviation from linearity (]Cl1-Mn-O4 = 177.17(5)8).
Bite angles between each of the equatorial N3O2 donors and
axial Cl1 and H2O are > 908 and < 908, respectively, which
reveals that the Mn atom is lying slightly away (0.1103(10) )
from the mean basal plane towards the axial Cl1 atom. The
relatively long Mn-Cl1 bond distance indicates that the Cl1 is
weakly coordinated to the Mn2+ and likely to be replaced by
a water molecule in aqueous solution.[22b, 34] The E1-Mn1-E2
angles, where E1 and E2 denote equatorial donor atoms
(N3O2) of the PyCOHz plane, fall within the range 68.08–
70.248 which is very close to the 728 for ideal pentagonal
bipyramidal coordination.
The analogous Zn2+ complex ZnLMe is isostructural
(Figure S6) with the Mn2+ complex MnLMe and the Zn2+ ion
lying very close (0.078(2) ) to the basal N3O2 plane. Within
the structures of each complex, there are intermolecular
hydrogen bonds between the complex (water, chloride) and
further unbound water and chloride. The extensive 3D
hydrogen-bonding network in the solid state for MnLMe is
described and illustrated in the supporting information (Fig-
ure S7). Crystallographic data and selected bond distances
and angles of both the complexes (MnLMe and ZnLMe) are
summarized in Tables S1–S10. Also, it is worth noting that the
crystal structures of MnLMe and ZnLMe are similar to those of
the analogous complexes [M(DAPSC)(Cl)(H2O)]Cl·2H2O
for M = Mn, Zn (where DAPSC = 2,6-diacetylpyridine bis(-
semicarbazone).[24] These differ only in the ligand (the pair of
terminal methyl groups in LMe are NH2 in DAPSC) and this is
reflected in the crystal structure (See SI).
Relaxometry Studies
The longitudinal proton relaxivity r1 is the measure of the
contrast capability of the agent (per unit of agent per second).
The longitudinal relaxation times (T1) of MnL
Me at different
concentrations were measured at both 400 MHz (9.4 Tesla)
and 64 MHz (1.5 Tesla) at 298 K. The relaxivity values r1 of
MnLMe at 9.4 and 1.5 T were determined as 4.88 0.4 and
5.2 mM1 s1, respectively, from the slope of corresponding
plots of 1/T1 vs. [MnL
Me] (Figure S8). To corroborate the MR
capability of MnLMe, T1-weighted phantom MR images of the
complex at different concentrations (0.1–0.5 mM and 1–
5 mM) and Magnevist (clinically available acyclic GdCA,
[Gd(DTPA)(H2O)]
2) were evaluated using 7 T preclinical
and 1.5 T clinical MRI systems, respectively (Figures 3 and
S8). The relaxivity of MnLMe is attributed to the presence of
two coordinated water molecules (it is postulated that the
bound Cl anion in the crystal structure is replaced in situ).
MnLMe displays enhanced relaxivity in comparison to the
reported monohydrated Mn2+ complexes and comparable r1
to the bishydrated.[23, 25] MnLMe also shows a higher r1 value in
comparison to that of Gd-DTPA (3.6 mM1 s1 at 1.5 T and
7 T 298 K); this is reflected in the phantom image of Gd-
DTPA at 1 mM concentration (Figure S8). The pentacoordi-
nate planar and rigid structure of the pyridyl carbohydrazone
may also influence the electronic spin relaxation times of
Mn2+ ion and shortening the residence lifetime of the inner-
sphere water molecules.[22b,c,23]
The r1 value is inversely proportional to the length of the
intramolecular metal-water bond. So, the increased bond
length between the metal ion and coordinated water molecule
(M-Owater) suggests a more labile bond that could undergo
rapid displacement with bulk solvent water.[25b, 33a,35] However,
in this complex, the bond length of Mn-Owater is found to be
2.173(2)  which is shorter than the Mn-Cl distance (2.499-
(8) ) suggesting the Cl can be replaced with water molecules
from the bulk and form a bishydrated complex in the aqueous
solution[22b] leading to enhanced relaxivity compared to
reported monohydrated Mn2+ complexes.[19b, 20c,28b] Moreover,
the distance between the water protons and Mn2+ ions
(Mn···Hwater) was found to be 2.74 , which enables efficient
dipole-dipole coupling between the water protons and para-
magnetic metal ion.[29b, 36]
The other important parameter for MnCAs is the kinetic
inertness of the complex, crucial to in vivo application, which
can be correlated with ligand transmetallation rates. We have
performed a series of transmetallation experiments to ascer-
tain the chelating and kinetic stability of MnLMe. Trans-
metallation of MnLMe was assessed and compared with the
bench mark CAs including [Mn(EDTA)(H2O)]
2, [Mn-
(DTPA)]3 and [Gd(DTPA)(H2O)]
2 in the presence of
Zn2+ (5/25 molar equivalent) in 50 mM MES/HEPES at
pH 6.0/7.4 (400 MHz, 9.4 T, 298 K). The initial water proton
relaxation rates (R1 = 1/T1) of MnL
Me (1 and 2 mM) were
observed as 5.78 0.5 and 9.86 s1, which increased slightly
(R1 6.15 0.4 and 10.69 s1) upon addition of a 5 and 25
molar equivalent excess of Zn2+, respectively. This suggests
a minor increase in molecular weight possible through the
association of Zn2+ to the NH groups (m/z = 439.31 ZnLMe +
Zn, Figure S5). Nevertheless, small and negligible fluctua-
tions in R1 were observed for MnL
Me with the excess (5 and
25 molar equivalent) of Zn2+ over the remaining 60 and
15 days of the experiment, respectively (Figures S9–S11).
Figure 1. (Top) ORTEP diagram of the asymmetric unit of MnLMe with
atoms drawn as 50% thermal ellipsoids. The dashed lines show
classical hydrogen bonds within the asymmetric unit.[53]
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Notably, MnLMe displays remarkable (21, 50 and 9-fold)
kinetic inertness toward Mn2+ transmetallation than the
[Mn(EDTA)(H2O)]
2, [Mn(DTPA)]3 and [Gd(DTPA)-
(H2O)]
2, respectively, since their R1 values were substantially
increased from 3.14 0.16, 1.84 0.2 and 5.28 0.4 s1 to
7.35 0.4, 7.66 0.7 and 8.29 1.1 s1, respectively, after
addition of 25 molar equivalent of Zn2+ in 50 mM MES
buffer at pH 6.0, 298 K.
In order to ascertain the Mn2+ and Gd3+ displacements
precisely in MnLMe and [Gd(DTPA)(H2O)]
2, the transme-
tallation kinetics were recorded by measuring water T2
(Mn2+) and T1 (Gd
3+), respectively, over 900–950 seconds
(Figure 2). Interestingly, MnLMe displays higher inertness
(pseudo-first-order, k = 8.9  103 s1) to Zn2+ (25 equivalent
excess) than the [Gd(DTPA)(H2O)]
2 (k = 1.6  102 s1).
Notably, the k value obtained for GdCA such as Gd(DTPA)-
(H2O)]
2 is similar to the value reported in the literature.[28b]
This indicates that MnLMe shows high inertness to Zn2+ even
when compared to commercially available GdCAs.
The time-dependent electronic absorption spectral study
was also carried out to prove the chelating stability of the
MnLMe in aqueous (50 mM HEPES buffer) solution at pH 7.4
over a week. The absorption spectrum of the MnLMe is
characterized by two intense bands at 213 and 275 nm.
(Figure S12). The calculated absorption intensity ratios
(Abs275nm/Abs213 nm) of MnL
Me at pH 7.4 are relatively con-
stant over a week suggesting that its reasonably stable at
physiological conditions.
To show the stability of MnLMe outside of physiological
conditions the r1 of the MnL
Me has been investigated at seven
different pH conditions including 3.0, 5.2, 6.0, 7.3, 8.5, 9.3 and
10.0 (Figure S13) (9.4 T, 298 K). Interestingly, the r1 values
between pH 3.0 and 7.3 are found to be 4.01 0.3, 4.43 0.2,
4.53 0.2, 4.88 0.2 mM1 s1, respectively. Only a slight
decrease in r1 values observed at lower pH conditions suggest
that it may be due to the protonation of imino nitrogen atoms
that led to increased chelating stability rather than stepwise
dissociation of MnLMe under acidic conditions. This was
further supported by the high protonation constant value
(KH> 13) for imino nitrogen containing compound with
similar (CH3)C=N-NH-CO moiety.
[37] Notably, presence of
methyl groups adjacent to imino nitrogen atoms facilitate to
preserve the hydrogen bonding that stabilize the molecule at
acidic conditions. However, the r1 values at pH 8.5 and 9.6
were observed as 4.56 0.3 and 3.64 0.2 mM1 s1, respec-
tively. A gradual dropping of the r1 values at pH> 8.5
indicates that it forms monohydrate/hydroxo complex
([MnLMe(H2O)(OH)]
+) under basic conditions. We also
observed yellow precipitation accompanied dropping of r1
value (0.01 mM1 s1) at pH 10.0. This is likely due to the
formation of insoluble bishydroxo complex.
The chelating stability of MnLMe with and without the
presence of challenging chelating agents (EDTA and DTPA)
was further analyzed by LC-MS method (Figure S14) using
CH3CN/NH4OAc buffer gradient (0–5% CH3CN over
10 min) at pH 7.0, 298 K. Notably, there was no considerable
change (retention time of MnLMe at 8.7 min) even after
incubating (30 min) with 25 molar equivalent excess of DTPA
or EDTA.
The data indicates that the Schiff-base type MnLMe is
highly inert to trans-chelation even under high-stress con-
ditions and suggest that the thermodynamic stability of
MnLMe is comparably higher than the benchmark Mn-
complexes ([Mn(EDTA)(H2O)]
2 and [Mn(DTPA)]3) with
reported pM values > 7.7 (pM =log[MnIIfree]).[28b] Further-
more, we have accessed the in vivo stability of MnLMe after
injection of a clinical dose of MnLMe in a healthy mouse.
Urine samples were collected, analyzed by LC-MS, and
quantified by the Evan method at 14.1 T (Figure S15). At
40 min post intravenous MnLMe (0.1 mmol kg1 bodyweight,
2.5  106 M) injection, 24.24% of the applied MnLMe was
excreted into the bladder in an intact form. This further
confirms that MnLMe is being excreted intact form, with no
signs of transmetallation or trans-chelation by other biogenic
metals or biomolecules, respectively, suggesting superior
thermodynamic stability and kinetic inertness in vivo.
NMRD and 17O-NMR Analyses
To gain more insight in the relaxivity values observed for
MnLMe, we have recorded 1H Nuclear Magnetic Relaxation
Dispersion (NMRD) profiles in aqueous solution at 283, 298
and 310 K in the proton Larmor frequency range 0.01–
120 MHz, corresponding to magnetic field strengths varying
between 2.34  104 and 2.81 T (Figure S16). The temper-
ature-dependent 1H-NMRD profiles of MnLMe are typical of
monomeric, low molecular weight complexes, featuring a low-
field plateau (0.01–1 MHz) followed by a dispersion about
4 MHz and another region of nearly constant relaxivity values
above 20 MHz.[38] In these cases, the r1 is limited to a large
extent by the rotational correlation time, as typically observed
in clinically used GdCAs.[39] Support for this conclusion comes
from the temperature dependency of r1 that decreases with
increasing temperature across the entire frequency range
investigated. Then, we can infer that MnLMe is in the fast-
water exchange regime[38b,39] as further confirmed by the
quasi-exponential decrease of the relaxivity with the increase
Figure 2. Transmetallation of MnLMe (*) and [Gd(DTPA)(H2O)]
2 (*)
were separately incubated with 25 mol excess Zn2+ at pH 6.4 in 50 mM
TRIS buffer. The T1 of water protons was measured using a Bruker
NMR spectrometer (B0 =14.1 T) over 900–950 seconds. The fitted lines
reflect pseudo-first order rate constants for dissociation of free Gd3+
from [Gd(DTPA)(H2O)]
2 and free Mn2+ from MnLMe.
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in temperature in the range 285–325 K (22 MHz; Figure S17).
A least-squares fit of the profiles of MnLMe was carried out
according to the established theory of paramagnetic relaxa-
tion expressed by the Solomon-Bloembergen-Morgan and
Freeds equations for the inner- (IS) and outer sphere (OS)
proton relaxation mechanisms, respectively.[25a,c]
The hydration state of Mn2+ was confirmed by applying
the empiric equation recently suggested by Peters and
Geraldes.[40] Using this approach, we obtained q = 2.3 0.4,
which is in excellent agreement with the determined q = 2
value. Finally, the diffusion coefficient (298DMnH) and its
activation energy (EDMnH) were fixed to the values for the self-
diffusion of water molecules in pure water.[41]
The temperature dependence of 17O NMR transverse
relaxation rates allow an accurate assessment of the value of
the water exchange rate kex (kex = 1/tM).
[25c,39] The R2 values,
normalized to the concentration of 1 mM (r2) and shown in
Figure 3A, increase with increasing temperature tending to
reach a broad maximum that is estimated around 350 K. This
indicates a changeover from a slow exchange situation, at
lower temperatures, to an intermediate exchange regime at
higher temperatures. The data is typically analysed using the
well-known Swift–Connick equations.[21b,39]
A global fit of the 1H and 17O NMR data was performed
using as adjustable parameters tR, the electronic relaxation
parameters D2 (trace of the squared zero-field splitting, ZFS,
tensor), and 298tV (correlation time for the modulation of the
transient ZFS), the residence lifetime of the bound water
molecules 298tM, the hyperfine coupling constant AO/h, the
enthalpy of activation of tM, DHM, and the activation energy
of tV, EV. The experimental data could be accurately
reproduced with the parameters listed in Table 1 (a complete
set of fitting parameters is reported in Table S11). The
rotational correlation time (298tR) obtained for MnL
Me is fully
comparable with that of [Mn(EDTA)(H2O)]
2, as expected
based on the similarity of their molecular sizes.[21a] Further-
more, this value confirms the previous qualitative analysis of
the limiting role of 298tR on relaxivity, particularly at the
magnetic fields relevant for clinical imaging. Instead, the
parameters related to the relaxation of the electron spin of the
Mn2+ ion, D2 and its associated correlation time tV, are quite
different from those of [Mn(EDTA)(H2O)]
2 and [Mn-
(H2O)6]
2+. This reflects the presence of somewhat different
coordination environments of the metal ion in the complexes.
The water exchange rate calculated for MnLMe is 5.2  106 s1.
This value is significantly lower than that of many anionic or
neutral complexes measured so far (e.g. [Mn(dpama)] and
[Mn(EDTA)(H2O)]
2 ;[25a–c] Table S11) but it is quite similar to
that reported for a structurally related complex featuring the
same overall electric charge.[16] The maximum value of r2
cannot be experimentally determined for this complex, but
only extrapolated from the calculated curve. However, it can
be used to get a rough estimate of the hydration number of
MnLMe, using the method proposed by Gale et al.[42] We
obtained a q value of 1.7, confirming the presence of two
inner-sphere water molecules in the complex.
Figure 3. A) Temperature dependent17O NMR transverse relaxation
rates of MnLMe free (blue diamonds) and bound to BSA (red circles).
B) 1/T1 NMRD profiles measured at 298 K of MnL
Me free (black) and
bound to BSA (blue). C) Water proton relaxation rate (R1
obs) as
a function of BSA concentration for a 0.1 mM solution of MnLMe in
50 mM HEPES buffer at pH 7.4, 298 K, and 32 MHz. D) Emission
spectral trace of 50 mM BSA protein in 50 mM HEPES buffer (pH 7.4,
298 K) with increasing quantity of complex MnLMe (0–150 mM,
lex = 280 nm); and inset Stern–Volmer plot of emission intensity F0/F
vs. [MnLMe] . E) T1-weighted imaging and T1-maps of 0.1–0.5 mM
MnLMe solutions (top row) and MnLMe at the same concentrations with
0.6 mM BSA (bottom row). Samples were prepared in 50 mM HEPES
buffer at pH 7.0, and imaging was performed at 7.0 T and 310 K.
Table 1: Selected best-fit parameters obtained from the analysis of the 1/
T1 NMRD profiles and
17O NMR data of MnLMe and its BSA adduct.
Parameters [MnLMe]2+ [Mn(dpma)][c]
298r1 20 MHz [mM
1 s1][a] 5.70.2 5.3
298tRL [ps] 52.00.1 47.8
298kex [ 10
6 s1] 5.20.2 3.3
DHM [kJmol
1] 29.71.2 28.1
q 2 [b] 2
Parameters MnLMe/BSA[e] Mn(DPAC12A)/HSA[d]
298r1
b 20 MHz [mM1 s1][a] 21.10.7 15.5
KA [M
1] 4.20.3  103 1.4  105
298tRG [ns]
[b] 50[b] 50
298tRL [ps] 40835 306
298kex [ 10





[a] value obtained at 32 MHz, [b] fixed during the fitting procedure,
[c] ref. [25b] and [d] from ref. [25a], [e] [BSA]= 1.43 mM.
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Serum Protein Binding
Non-covalent interaction of paramagnetic complexes with
slowly tumbling natural biological macromolecules such as
proteins enhances the r1 by lengthening the rotational
correlation time tR.
[39, 43] However, the preparation of such
macromolecule binding contrast agents requires multiple
synthetic steps when compared to small contrast agents.
Proton Relaxation Enhancement (PRE) approach has been
used to investigate the non-covalent binding interaction of
MnLMe with BSA in aqueous solution at 32 MHz, neutral pH,
and 298 K. The method is based on the measurement and
analysis of the variation in the relaxation rate R1 of the solvent
water protons following the addition of increasing amounts of
the protein to a 0.1 mM solution MnLMe. R1 was measured
before and following the addition of different amounts of
BSA, covering a concentration range between ca. 0.01–
1.3 mM (Figure 3 C). The observed relaxation rate, R1
obs,
increases with the progressive additions of BSA, due to the
concomitant increase in the protein-bound molar fraction of
the complex and tends to an asymptotic value associated with
the relaxivity of the bound complex, r1
b (Figure 3C). The
analysis of this isothermal binding curve in terms of PRE
equations allows us to extract fairly accurate values of the
relaxation of r1
b (21.1 0.7 mM1 s1) and of the term nKA
(4.2  103 M1), where n represents the number of equivalent
and independent binding sites and KA is the affinity con-
stant.[44] All the data were fitted to a 1:1 binding isotherm
even though the presence of multiple low-affinity sites on
BSA cannot be strictly excluded. Association constants with
very similar values, in the case of human serum albumin, have
been reported for macrocyclic MnII complexes functionalized
with benzyl groups.[45] The NMRD profiles of the BSA adduct
was measured at 298 K (Figure 3B) for a diluted solution
(0.1 mM) of MnLMe in the presence of 1.3 mM BSA. These
conditions ensure more than 99% binding of MnLMe to the
protein.
In several cases, the interaction of bishydrated complexes
(q = 2) of GdIII with the protein was accompanied by
a reduction in the state of hydration and the exchange rate
of the inner sphere water molecule(s).[46] To better evaluate
these aspects and obtain an accurate estimate of kex, we
measured the temperature dependence of 17O NMR R2 in
a solution of MnLMe (0.12 mM) containing an excess of BSA
(1.43 mM) in HEPES. The temperature dependency of the r2
values is reported in Figure 3A and visually clearly indicates
the lower hydration state of the complex bound to the protein,
as testified by a marked reduction of r2 values at all explored
temperatures respect to what observed for the free chelate.
The 1H and 17O NMR data were analysed as in the previous
case. The NMRD profile was fitted only in the high-field
region (> 3 MHz) because of the known limitations of the
SBM theory for slowly tumbling systems at low magnetic field
strengths.[47] The NMRD profile analysis was performed using
the Lipari-Szabo approach for the description of rotational
dynamics.[48] This model takes into consideration the occur-
rence of the anisotropic motion condition, which is attribut-
able to a certain degree of local rotation at the binding site
superimposed on the global rotational motion of the protein.
The two types of motions are characterized by different
correlation times: tRL and tRG, respectively. The degree of
correlation between the two types of motion is expressed by
the order parameter S2, which takes values between 0
(completely independent motions) and 1 (completely corre-
lated movements). The data is reproduced satisfactorily using
the value of 1 (Figures 3A,B, and Table 1) for q. The
reduction of q from 2 to 1 implies the formation of a ternary
complex with the protein, with a displacement of a water
molecule from a coordinating group of BSA, easily an acetate.
Derivatives of [Gd(DO3A)(H2O)] with pendant hydro-
phobic chain have been reported to form ternary adducts with
HSA characterized by completely analogous KA values and
water displacement from the protein. Even in this case, we
have confirmed the value of q from the maximum value of 17O
NMR r2 calculated from the best-fit curve (q 0.9). The data
analysis also indicates a 2-fold slower kex compared to the free
complex (kex = 2.6  10
6 s1; tM = 378 ns).
This decrease in the water exchange rate may be due to
a lower accessibility of bulk water to the metal ion at the
binding site, or to the involvement of water bound in
hydrogen bonds with proximate groups of the protein.
The analyses of the NMRD profile using the Lipari-Szabo
model (Table 1) indicate that a high degree of local flexibility
is responsible for the relatively low relaxivity of the adduct
formed between MnLMe and BSA, consistent with the low
values of tRL and S
2. To further validate the protein binding
affinity of MnLMe and the number of binding sites available in
BSA for MnLMe, fluorescence spectral titrations of BSA
versus MnLMe and Mn2+ (Figures 3D and S18) in 50 mM
HEPES buffer at pH 7.4, 298 K were carried out. As
expected, the initial fluorescence intensity of BSA (50 mM)
at 355 nm was dramatically decreased upon the addition of an
equivalent of MnLMe (0–150 mM) and became relatively
constant to significant excess. The linear relationship sharply
deviated when plotting F0/F vs. [MnL
Me], and an upward
curvature was observed. This is due to the interaction of
MnLMe with BSA in its ground state (static quenching) and its
first excited singlet state (dynamic quenching) as well. The
average association constant KA and the number of binding
sites (n) in BSA (from modified Scatchard plot analysis)[49]
are found to be 4.02  103 M1 and 1.0, respectively, correlat-
ing with the PRE experiment. In contrast, there is no
considerable fluorescence quenching upon addition of Mn2+
(Figure S18), thus suggesting that the ligand moiety in MnLMe
is essential for the BSA binding.
In support of the previous experiments, we also performed
T1- and T2- weighted phantom imaging at 7.0 T with MnL
Me
solutions at different concentrations, with and without BSA
(Figures 3 E and S19). Results show that the T1-contrast
enhancement was only modest in the samples containing
MnLMe in solution but highly enhanced in the presence of
0.6 mM BSA (Figure 3E). Moreover, as expected, we ob-
served a superior T2-contrast modulation from MnL
Me at 7 T
(Figure S19). This is due to the favorable transverse para-
magnetic relaxation properties of Mn2+ at a high magnetic
field compared to Gd3+.[42]
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In Vivo MRI Studies
Dynamic T1-weighted MRI measurements were per-
formed in healthy mice to evaluate the potential of MnLMe
as an MRI CA. Figure 4A shows the pre- and post-contrast
(7 min) coronal MR images following the intravenous in-
jection of 0.1 mmolkg1 MnLMe. Elimination is observed
through the liver, kidneys, and the bladder. Contrary to
previously reported MnCAs, no significant contrast enhance-
ment was found in the gallbladder.[50] Regardless, the
distribution of MnLMe followed similar pathways previously
observed for small Mn- and Gd-based complexes.[28b, 29a, 50] For
comparison, we have performed dynamic MRI studies with




) (bolus of 0.1 mmolkg1).[17a,51] Figur-
es 4B and S20 clearly show that MnLMe provides similar
normalized change in signal intensity (DSI) values in the
kidneys over the 40 min imaging time, denoting the fast
clearance of the agent.
The higher contrast produced by MnLMe in the liver over
the 40 min suggests a slower clearance through the liver. This
is also confirmed by lower contrast in the bladder due to the
gradual elimination. In Figure 4C, we compared the area-
under-the-curve (AUC) for each tissue over the imaging time
of 40 minutes post-injection (AUC0–40min). Results showed
that both compounds indeed present similar excretion path-
ways; however, the kidney-to-liver AUC0–40min ratio for both
agents indicates a slower clearance of MnLMe (Figure 4C).
Although not reaching statistical difference, data also suggest
a longer half-life in the blood, as observed by the higher DSI
values on the left ventricle of the heart (Figure S20). This
feature enables for a longer image acquisition window after
bolus injection and avoids the use of highly concentrated
doses of CAs by constant infusion.[52] Since albumin is the
most abundant protein in the blood with an average concen-
tration of 0.6 mM, any enhanced contrast observed in the T1-
weighted imaging results from specific MnLMe binding to
murine serum albumin in vivo. While further studies are
necessary to test the fraction of MnLMe bound to serum
albumin in vivo, the presented in vivo data indicates safe use
of MnLMe as a specific MRI blood pool contrast agent.
Conclusion
We have designed and synthesized a new pentadentate
Schiff-base type Mn2+ complex (MnLMe) in a one-pot
reaction, interrogated its structural, stability, kinetic inertness,
relaxometric properties and explored its biodistribution in
healthy mice using in vivo MRI. This is the first example to
date of template to MRI contrast agent synthesis. This non-
macrocyclic Mn2+ complex displays relatively enhanced water
proton relaxivity (r1) 4.88 and 5.2 mM
1 s1 at 400 MHz
(9.4 T) and 64 MHz (1.5 T), respectively, compared to the
reported acyclic mono and bishydrated Mn2+ and Gd3+
complexes. The pH-dependent relaxivity and zinc transme-
tallation kinetics study results confirm that the complex is
stable at neutral pH conditions. The MnLMe shows a moderate
Figure 4. A) Representative T1-weighted MR images illustrate contrast
enhancement in the kidneys, liver, heart, and bladder after application
of MnLMe at a clinical dose (right panel) in comparison to pre-contrast
imaging (left panel). B) Percentage of signal intensity enhancement
normalized to muscle for all organs of interest revealed a comparable
dynamic excretion profile for MnLMe and Magnevist in liver and kidneys
(mean  SEM, n = 3 for MnLMe, n =3 for Magnevist). C) (left panel)
Total signal intensity over time of MnLMe represented as the area under
the curve (AUC0–40 min (DSI*min)) is significantly higher in the liver
and lower in the bladder compared to Magnevist (mean  SEM, n = 3
for MnLMe, n = 3 for Magnevist). (right panel) The kidney-to-liver ratio
of total signal intensity represented as area-under-the-curves (AUC0–
40 min (DSI*min)) is significantly lower for MnLMe compared to
Magnevist

(mean values  variance, n = 3 for MnLMe, n =3 for
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binding affinity with BSA, which results in enhanced relax-
ivity upon binding due to the decreased molecular rotation.
The concentration-dependent signal enhancement in the
phantom T1-weighted MR images suggests that the capability





have demonstrated this in vivo in healthy mice by MRI. The
clearance of MnLMe follows a renal/hepatic elimination
pathway. MnLMe is excreted intact into the bladder and shows
a delayed clearance from the blood as observed by the
continuous high DSI on the left ventricle of the heart. As in
vitro data indicates that MnLMe interacts with albumin and




), MnLMe will be further
investigated as a potential MRI blood pool contrast agent.
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46, 2459 – 2470; c) E. Moln	r, N. Camus, V. Patinec, G. A. Rolla,
Angewandte
ChemieResearch Articles
&&&&Angew. Chem. Int. Ed. 2021, 60, 2 – 11  2021 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH www.angewandte.org
These are not the final page numbers!  
M. Botta, G. Tircs, F. K. K	lm	n, T. Fodor, R. Tripier, C. Platas-
Iglesias, Inorg. Chem. 2014, 53, 5136 – 5149.
[23] B. Phukan, C. Mukherjee, U. Goswami, A. Sarmah, S. Mukher-
jee, S. K. Sahoo, S. C. Moi, Inorg. Chem. 2018, 57, 2631 – 2638.
[24] G. J. Palenik, D. W. Wester, Inorg. Chem. 1978, 17, 864 – 370.
[25] a) A. Forg	cs, M. Regueiro-Figueroa, J. L. Barriada, D. Esteban-
Gmez, A. de Blas, T. Rodrguez-Blas, M. Botta, C. Platas-
Iglesias, Inorg. Chem. 2015, 54, 9576 – 9587; b) A. Forg	cs, R.
Pujales-Paradela, M. Regueiro-Figueroa, L. Valencia, D. Este-
ban-Gmez, M. Botta, C. Platas-Iglesias, Dalton Trans. 2017, 46,
1546 – 1558; c) S. Aime, M. Botta, D. Esteban-Gmez, C. Platas-
Iglesias, Mol. Phys. 2019, 117, 898 – 909; d) N. Rastogi, N. Tyagi,
O. Singh, B. S. Hemanth Kumar, U. P. Singh, K. Ghosh, R. Roy,
J. Inorg. Biochem. 2017, 177, 76 – 81; e) B. Drahoš, E. Lukes, E.
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